
PFE
Pfizer Inc.
Biopharmaceutical vaccines, oncology therapeutics, cardiovascular immunology medicines. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
1
$2.96M
Insider Sales
0
$0
Total Volume
$2.96M
7 transactions
Net Activity
+$2.96M
Net buying
Sentiment Rating
Moderate AccumulationCEO Conviction Index
No Recent Signal
Key Drivers
- •Strong buying bias: purchases represent 100% of total transaction value.
- •High accumulation: total purchase value exceeds $1M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Multiple Insiders
3 Insiders
$17.20B total
Quick Actions
PFE has an insider buy conviction of 100%, compared to the Pharmaceuticals sector buy average of 0%.
Over the last 90 days, corporate insiders at Pfizer Inc. (PFE) engaged in a total of 7 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 0 were sales. The total volume of insider trading reached $2.96M.
The net insider activity for PFE shows a net buying bias of $2.96M. This activity represents a 100% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 435.6K shares valued at $16.55B on Aug 12, 2026.
One Unsettled Question Sits Under Pfizer Stock
Pfizer (PFE) Re Enters Obesity Drugs With Metsera Acquisition
Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
Pfizer (PFE) Stock Looks Overvalued On Its 29% One Year Gain
FAQs About Pfizer Inc. Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for PFE.